Clinical data from the MYTHIC trial showed activity for lunresertib plus zedoresertib in platinum-resistant ovarian cancer, including higher response rates in the CCNE1-amplified subgroup. At the potential recommended phase 2 dose, investigators reported an overall response rate (ORR) of 50% in the overall population and 60% in the CCNE1-amplified subset. The results were presented by UT MD Anderson’s Timothy A. Yap. Across all dose levels, the overall ORR was 37.5%, and tumor shrinkage was observed in 80% of patients. Investigators also reported durability, with 37% remaining on treatment for longer than 16 weeks, and the FDA granted fast track designation for the targeted ovarian cancer biomarker population.